Catabasis Pharmaceuticals, Inc.
161 First Street
Suite 1A
Cambridge
Massachusetts
02142
United States
Tel: 617-349-1971
Fax: 617-273-2637
Website: http://www.catabasispharma.com/
Email: info@catabasispharma.com
211 articles about Catabasis Pharmaceuticals, Inc.
-
Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress
5/12/2020
Top-Line Results Expected in Q4 2020 from Fully Enrolled Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy
-
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy
5/12/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today shared information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) in poster presentations at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session. The three posters include an analysis of the baseline characteristics of patients enrolled in the Phase 3 Polari
-
Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session
4/17/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) at the 2020 Muscular Dystrophy Association (MDA) Virtual Poster Session later this month. During the Virtual Poster Session, Catabasis and collaborators will present three poster
-
Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference
3/25/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, plans to present a corporate overview and provide a business update at the upcoming Solebury Trout Virtual Investor Conference on Tuesday, March 31, 2020 at 12:30pm EDT. A webcast of the presentation will be available in the investors section of the Company’s websit
-
Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session
3/18/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) during the Muscular Dystrophy Association (MDA) Virtual Clinical Trials Session on Tuesday, March 24, 2020.
-
Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress
3/10/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2019 and reviewed recent business progress.
-
Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th
2/25/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, will report fourth quarter and full year 2019 financial results before the Nasdaq Global Market open on Tuesday, March 10, 2020. Jill C. Milne, Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss fourth quarter and last year’s financial results.
-
Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy
2/21/2020
Feb. 21, 2020 13:00 UTC BOSTON--( BUSINESS WIRE )-- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy, organized by Parent Project, in Rome, Italy. Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer of Catabasis Pharmac
-
Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option
2/3/2020
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of an aggregate of 5,290,000 shares of common stock at a public offering price of $5.00 per share
-
Catabasis Pharmaceuticals Announces Pricing of $23 Million Underwritten Public Offering
1/30/2020
Catabasis Pharmaceuticals, Inc. (“Catabasis,” the “Company,” “we,” “our,” or “us”) (NASDAQ: CATB), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of an aggregate of 4,600,000 shares of common stock at a public offering price of $5.00 per share
-
Catabasis Pharmaceuticals Announces Proposed Underwritten Public Offering - Jan. 29, 2020
1/29/2020
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer its securities in an underwritten public offering.
-
Catabasis Pharmaceuticals and Duchenne UK Announce Partnership to Evaluate Edasalonexent in a Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
1/8/2020
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular dystrophy (DMD), have entered into a partnership for a Phase 2 trial of edasalonexent, a novel NF-kB inhibitor, in non-ambulatory DMD patients
-
Catabasis Pharmaceuticals Announces Phase 3 PolarisDMD Trial Enrolled Expected Patient Population
12/16/2019
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced the results from an analysis of the baseline characteristics of the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD).
-
Catabasis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Reviews Business Progress
11/7/2019
Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Fully Enrolled with Top-Line Results Expected in Q4 2020
-
Catabasis Pharmaceuticals to Present Third Quarter 2019 Financial Results and Recent Corporate Developments on Thursday, November 7th
10/24/2019
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, will report third quarter 2019 financial results before the Nasdaq Global Market open on Thursday, November 7, 2019.
-
Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
10/18/2019
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the Child Neurology Society 48th Annual Meeting to be held October 23-26 in Charlotte, North Carolina.
-
Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Treatment for Duchenne Muscular Dystrophy
10/5/2019
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented the findings from the MoveDMD trial of edasalonexent
-
Catabasis Pharmaceuticals Announces the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy has Exceeded Target Enrollment
9/30/2019
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today the completion of enrollment for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD).
-
Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society
9/27/2019
Catabasis Pharmaceuticals, Inc. announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy will be presented at the 24th International Congress of the World Muscle Society, being held October 1-5, 2019, at the Tivoli Garden Concert Hall in Copenhagen, Denmark.
-
Catabasis Pharmaceuticals and the Jain Foundation Announce a Preclinical Research Collaboration to Study Edasalonexent in Dysferlinopathy
9/26/2019
Edasalonexent Inhibits NF-kB, a Potential Driver of Disease Progression in Dysferlinopathy